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Abstract 
Background: Cycling hypoxia is a well‑recognized phenomenon within animal and human solid tumors. It con‑
tributes to the resistance to cytotoxic therapies through anti‑apoptotic effects. However, the mechanism underlying 
cycling hypoxia‑mediated anti‑apoptosis remains unclear.
Methods: Reactive oxygen species (ROS) production, activation of the hypoxia‑inducible factor‑1 alpha (HIF‑1α) and 
nuclear factor‑κB (NF‑κB) signaling pathways, B‑cell lymphoma extra‑long (Bcl‑xL) expression, caspase activation, and 
apoptosis in in vitro hypoxic stress‑treated glioblastoma cells or tumor hypoxic cells derived from human glioblastoma 
xenografts were determined by in vitro ROS analysis, reporter assay, western blotting analysis, quantitative real‑time 
PCR, caspase‑3 activity assay, and annexin V staining assay, respectively. Tempol, a membrane‑permeable radical 
scavenger, Bcl‑xL knockdown, and specific inhibitors of HIF‑1α and NF‑κB were utilized to explore the mechanisms of 
cycling hypoxia‑mediated resistance to temozolomide (TMZ) in vitro and in vivo and to identify potential therapeutic 
targets.
Results: Bcl‑xL expression and anti‑apoptotic effects were upregulated under cycling hypoxia in glioblastoma cells 
concomitantly with decreased responses to TMZ through ROS‑mediated HIF‑1α and NF‑κB activation. Tempol, YC‑1 
(HIF‑1 inhibitor), and Bay 11‑7082 (NF‑κB inhibitor) suppressed the cycling hypoxia‑mediated Bcl‑xL induction in vitro 
and in vivo. Bcl‑xL knockdown and Tempol treatment inhibited cycling hypoxia‑induced chemoresistance. Moreover, 
Tempol treatment of intracerebral glioblastoma‑bearing mice combined with TMZ chemotherapy synergistically sup‑
pressed tumor growth and increased survival rate.
Conclusions: Cycling hypoxia‑induced Bcl‑xL expression via ROS‑mediated HIF‑1α and NF‑κB activation plays an 
important role in the tumor microenvironment‑promoted anti‑apoptosis and chemoresistance in glioblastoma. Thus, 
ROS blockage may be an attractive therapeutic strategy for tumor microenvironment‑induced chemoresistance.
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Background
Hypoxia is well evidenced within most solid tumors [1]. 
Acute, intermittent, and cycling hypoxia are associated 
with inadequate blood flow, whereas chronic hypoxia 
is the consequence of increased oxygen diffusion dis-
tance, resulting from tumor expansion [2]. These hypoxic 
areas can either promote cell death or provoke an adap-
tive response, leading to the selection for death resist-
ance [3–5]. Once tumor cells adapt to hypoxia, they are 
more resistant to apoptosis and less responsive to cancer 
therapy. We recently showed that cycling hypoxia and 
chronic hypoxia are important tumor microenvironment 
phenomena that limit tumor response to chemotherapy 
in glioblastoma multiforme (GBM) [6]. Therefore, several 
potential mechanisms, including the lack of oxygen that 
is available for anti-tumor drugs to act, DNA over-rep-
lication, increased genetic instability, the anti-prolifera-
tive effect of hypoxia [7], increased multidrug resistance 
(MDR) linked to adenine triphosphate (ATP)-binding 
cassette (ABC) transporter [8, 9], are thought to play a 
role in cycling hypoxia-induced chemoresistance. How-
ever, the exact mechanisms triggered by cycling hypoxia, 
leading to resistance to apoptosis, remain unclear.
Previous studies indicated that the repetitive periods 
of hypoxia and reoxygenation could lead to an increased 
production of reactive oxygen species (ROS) [10, 11]. 
Moreover, NADPH oxidase subunit 4 (Nox4) is a critical 
mediator involved in cycling hypoxia-mediated ROS pro-
duction, tumor progression, and resistance to cytotoxic 
therapies in GBM [12–14]. Although ROS play an impor-
tant role in apoptosis induction under both physiologic 
and pathologic conditions, ROS have also anti-apoptotic 
effects in cancer cells through unknown mechanisms [15, 
16]. A recent study reported that ROS stimulates NF-κB 
signaling, resulting in a B-cell lymphoma extra-long (Bcl-
xL)-mediated resistance to drug-induced cell death [17]. 
Bcl-xL is a member of the Bcl-2 family of proteins and 
acts as a pro-survival protein by preventing the release 
of mitochondrial contents and caspase activation [18]. 
NF-κB can bind directly to Bcl-xL promoter to regulate 
its expression [19]. Furthermore, Bcl-xL is also one of 
hypoxia-inducible factor-1 (HIF-1) target genes because 
its promoter contains a hypoxia-responsive element 
(HRE) [20]. These observations point to the possibility 
that Bcl-xL is a critical contributor to cycling hypoxia-
mediated anti-apoptosis and resistance to cytotoxic 
therapies.
In the present study, we determined the impact and 
mechanism of cycling hypoxia on anti-apoptosis and 
chemoresistance in GBM. Our results show that cycling 
hypoxic stress significantly increases resistance to temo-
zolomide (TMZ) via Bcl-xL upregulation. ROS-mediated 
HIF-1α and NF-κB activation plays an essential role in 
cycling hypoxia-mediated Bcl-xL induction. Moreover, 
pretreatment with a ROS scavenger, Tempol, in intracere-
bral glioblastoma-bearing mice demonstrated a synergis-
tic suppression of tumor growth and increased survival 
rate in TMZ chemotherapy, suggesting that ROS block-
ade before drug administration and in combination with 
chemotherapy may be an effective approach to suppress 
tumor microenvironment-induced chemoresistance and 
further improve the efficacy of chemotherapy in GBM.
Methods
Cell culture
U251, U87 and GBM8401 glioblastoma cells were cul-
tured in DMEM (Life Technologies) supplemented with 
10 % fetal bovine serum (FBS), 10 mM HEPES, and 1 % 
penicillin–streptomycin.
In vitro hypoxic treatments
Cells were treated in Biospherix C-Chamber (Biospherix) 
inside a standard culture chamber by means of exhaust-
ing and gassing with 95  % N2 and 5  % CO2 to produce 
oxygen concentrations of 0.5–1  % at 37  °C to achieve 
hypoxic condition. Cells were treated with or without 
in  vitro non-interrupted hypoxic or cycling hypoxic 
stress as previously described [6]. Briefly, cell cultures 
were exposed to 3 cycles consisting of 0.5–1  % O2 for 
1 h interrupted by 5 % CO2 and air for 30 min for cycling 
hypoxic treatment and to persistent 0.5–1  % O2 for 4  h 
for non-interrupted hypoxic treatment.
Real‑time quantitative PCR (Q‑PCR)
Q-PCR analysis was performed as described previ-
ously [21]. The primers for quantitative analysis of 
Bcl-xL and the housekeeping gene 60S acidic ribo-
somal proteins were: Bcl-xL (F) 5′- GATCCCCAT 
GGCAGCAGTAAAGCAAG -3′ and (R) 5′- CCCCATCC 
CGGAAGAGTTCATTCACT -3′ and the house keep-
ing gene 60S acidic ribosomal protein (F) 5′-ACGA 
GGTGTGCAAGGAGGGC-3′ and (R) 5′-GCAAGTCGT 
CTCCCATCTGC-3′.
Western blot analysis
Cells and tissues were lysed and extracts were prepared 
as described previously [21]. Nuclear and cytoplasmic 
lysates were prepared with the CelLytic Nuclear Extrac-
tion Kit (Sigma-Aldrich) according to the manufacturer’s 
protocol. HIF-1α, p65 and Bcl-xL proteins in human cells 
were detected in 150 µg of cell extract using monoclonal 
anti-HIF-1α antibody (diluted 1:650; Novus), anti-p65 
antibody (diluted 1:500; Novus) and anti-Bcl-xL antibody 
(1:600; Novus). Western blots were normalized using 
a monoclonal anti-β-actin antibody (diluted 1:10,000; 
Sigma-Aldrich) for cell extracts and a monoclonal 
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anti- TATA box binding protein (TPB) (diluted 1:1,000; 
Sigma-Aldrich) for nuclear extracts.
Reporter assays
The HIF-1α-luciferase reporter plasmid derived from our 
previous study [10] and NF-κB-luciferase reporter plas-
mid (Clontech) were utilized to determine HIF-1 and 
NF-κB-dependent transactivation of luciferase activities, 
respectively. In the measurement of HIF-1 and NF-κB-
dependent transactivation of luciferase activities, the 
dual-luciferase reporter assay system (Promega) was 
used. U251 and U87 cells were transfected with each 
reporter construct and the TK-Renilla luciferase plasmid 
was used as a transfection control. Luciferase detection 
was performed 48 h after reporter construct transfection. 
Expression was calculated as the relative Firefly lucif-
erase activity normalized with respect to the activity of 
transfection control Renilla luciferase. To determine the 
role of Tempol, YC-1 or Bay 11-7082 in cycling hypoxia-
induced transcriptional activation of Bcl-xL, the stably 
Bcl-xL promoter-driven luciferase reporter-transfected 
U251 and U87 cells were incubated with Tempol (4 mM; 
Sigma-Aldrich), YC-1 (10  μM; Sigma-Aldrich) and Bay 
11-7082 (5  μM; Sigma-Aldrich) together with in  vitro 
cycling hypoxic stress for 4 h. Firefly luciferase activities 
were assayed and normalized to those of extract protein 
concentrations measured with the Bio-Rad protein assay 
kit (Bio-Rad). Luciferase activity was determined by mix-
ing 10  μL of extracts from 1 ×  105 cells and 100  μL of 
luciferase assay reagent (Promega) according to the man-
ufacturer’s instructions.
ROS levels analysis
ROS levels were assessed by using carboxy-2′7′-
dihydrodichlorofluorescein diacetate (H2DCFDA, 
Molecular Probes) to assess total ROS. Cells were incu-
bated with 5  μg/mL of H2DCFDA for 30  min, then 
washed with PBS, trypsinized and collected in 1  mL of 
PBS. Fluorescent stained cells were transferred to poly-
styrene tubes with cell-strainer caps (Falcon) and sub-
jected to FACScalibur instrument and FACSDiva 6.0 
software (BD Bioscience) for acquisition and analysis.
Vector constructions and viral transduction
The lentiviral vector pLKO AS2 (National RNAi Core 
Facility, Taiwan) was used as the backbone to generate 
a lentiviral reporter vector. The multiple cloning sites 
(MCS) of pTA-Luc vector (Clontech) was inserted with 
the cDNA fragment bearing −1075 to +617 Bcl-xL pro-
moter to drive the expression of firefly luciferase gene. 
The Bcl-xL promoter driven reporter gene cassette was 
amplified from promoter to SV40 ploy A on the con-
structed pTA-Luc vector using PCR and inserted into 
pLKO AS2 as pLKO AS2- Bcl-xL-p by XhoI and MluI 
restriction enzymes. The pGreenFire1-SFFV [12] was 
used to generate glioblastoma reporter cells bearing SFFV 
promoter-driven a dual optical reporter gene encoding 
both green fluorescence protein (GFP) and luciferase 
(Luc). Lentiviral vectors carrying short hairpin RNAs 
(shRNA)-targeting HIF-1α (5′- TGCTCTTTGTGG 
TTGGATCTA-3′) and p65 (5′- CGGATTGAGGAGA 
AACGTAAA -3′) and scrambled shRNA (http://rnai.
genmed.sinica.edu.tw/file/vector/C6-7/17.1.pLAS.Void.
pdf) were provided by National RNAi core facility, Aca-
demia Sinica in Taiwan. The lentiviral vector pLVCT-
tTR-KRAB (Addgene) was used to express Bcl-xL shRNA 
(Sigma-Aldrich) following the manufacturer’s protocol. 
Lentivirus production and cell transduction were carried 
out according to protocols described elsewhere [22, 23]. 
All constructs were confirmed by DNA sequencing. The 
U251, U87, GBM8401 cells bearing the SFFV promoter-
driven a dual optical reporter gene and Bcl-xL pro-
moter-driven Luc reporter gene were termed GBM8401/
SFFV-LucGFP, U251- Bcl-xL-P-Luc and U87- Bcl-xL-P-
Luc respectively.
Fluorescence‑activated cell‑sorting (FACS) analyses
Tumor tissues were disaggregated with an enzyme cock-
tail containing collagenase type III (Sigma), hyaluroni-
dase (Sigma), and collagenase type IV (Sigma), washed 
several times, and resuspended in phosphate-buffered 
saline (PBS) to produce a single cell suspension. Fluo-
rescence was measured using a FACScalibur instrument 
and FACSDiva 6.0 software (BD Bioscience). Tumor 
cells were gated according to DsRed expression and side 
scatter (SSC). The hypoxic subpopulations were further 
gated or isolated based on the analysis of Hoechst 3342 
and GFP fluorescence in dot plots. The control cells are 
derived from disaggregated the orthotopic GBM8401 or 
U87 xenografts, which are both Hoechst 3342 and GFP-
negative, and were set in the lower left quadrant of the 
plot. Same setting conditions were used thereafter, cell 
populations located outside of this quadrant of the plot 
were defined as either Hoechst 3342− and GFP+ cells 
(chronic hypoxic cells), Hoechst 3342+ and GFP+ cells 
(cycling hypoxic cells) or Hoechst 3342+ and GFP− cells 
(Normoxic cells).
Caspase‑3 activity and apoptosis assays
U251 and U87 cells expressing Tet-inducible Bcl-xL 
shRNA were pretreated for 48 h with Dox (0.04 μg/mL) 
to induce Bcl-xL knockdown and then exposed to in vitro 
hypoxic stress, either non-interrupted hypoxic or cycling 
hypoxic stress, before TMZ treatment. The caspase-
3-like protease activities were determined by the Cas-
pase-3 Colorimetric Activity Assay Kit (Sigma-Aldrich) 
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according to the manufacturer’s protocol. Briefly, Cell 
lysates were incubated with 2  mM Caspase-3 substrate 
(Ac-DEVD-pNA) in 1× assay buffer (20  mM HEPES, 
pH 7.4, 2  mM EDTA, 0.1  % CHAPS, 5  mM DTT) for 
90 min at 37 °C. The absorbance was read at 405 nm and 
the results were calculated using a p-nitroaniline calibra-
tion curve. Annexin V and propidium iodide staining was 
performed to determine cell apoptosis using the Annexin 
V-FITC Apoptosis Detection Kit (Sigma-Aldrich) for 
10 min at room temperature according to the manufac-
turer’s instructions, and then flow cytometric analysis 
was performed.
Cytotoxicity assay
Cells were treated with DMSO (vehicle control), Tempol 
(4  mM; Sigma-Aldrich), TMZ (250  μM; Sigma-Aldrich) 
and the combination of Tempol and TMZ after in vitro 
hypoxic stress or cell sorting. After incubation at 37  °C 
for 48 h, the medium was removed from each well, 15 μL 
3-94,5-dimethyl-2-yl-2,5-diphenyl-tetrazolium (MTT) 
(Sigma-Aldrich) solution (2 mg/mL) were added and the 
plates were incubated at 37 °C for 4 h. The reaction was 
stopped by the addition of 100  μL of isopropanol/HCl, 
and the absorbance at 570 nm was recorded on a μQuant 
plate reader (Bio-Tek).
Animal models
Eight-week-old male athymic nu/nu mice were used to 
establish animal tumor models. For the subcutaneous 
GBM xenograft model, 5 × 106 GBM8401- Bcl-xL-P-Luc 
cells were injected subcutaneously into the dorsal flank 
and small (80 ± 16.0 mm3) subcutaneous tumors devel-
oped 14  days later were used for animal imaging stud-
ies. For the orthotopic GBM xenograft model, 2  ×  105 
GBM8401/SFFV-LucGFP cells were harvested by trypsi-
nization and injected into the right basal ganglia of anes-
thetized mice. The tumors developed at 12  days after 
tumor implantation for evaluating the efficiency of ther-
apy studies. All animal studies were conducted according 
to the Institutional Guidelines of China Medical Univer-
sity and approved by the Institutional Animal Care and 
Use Committees of China Medical University (approval 
number 102-54-N).
In vivo treatment
For the bioluminescence imaging of in  vivo transcrip-
tional activation of Bcl-xL,
Mice bearing U87- Bcl-xL-P-Luc xenograft were 
received with vehicle, Tempol (250  mg/kg i.p.), YC-1 
(15  mg/kg i.p.) or Bay 11-7082 (10  mg/kg i.p.) fol-
lowed by in  vivo cycling hypoxic treatment. The proce-
dure for in  vivo cycling hypoxic treatment was carried 
out following published methods [14, 24]. Briefly, the 
tumor-bearing mice were exposed to continuous flow 
of a humidified gas mixture to induce in vivo hypoxia in 
6-liter hypoxia chambers. The mice were exposed to nor-
mal air (control) or 12 cycles of 10  min 7  % O2 breath-
ing interrupted by 10 min periods of normal air breathing 
for cycling hypoxic treatment. For the therapeutic study, 
intracerebral gioblastoma-bearing mice were randomly 
assigned to four different therapeutic groups: control 
(vehicle treatment), pretreatment of Tempol (250  mg/
kg i.p.), TMZ (5  mg/kg i.p.) or pretreatment of Tempol 
(250 mg/kg i.p.) + TMZ (5 mg/kg i.p.). The pretreatment 
of Tempol was performed at day 13 after tumor cell injec-
tion. Systemic TMZ treatment was performed for 5 days, 
starting on day 14 after tumor cell injection. Tumor 
progression was monitored by bioluminescence imag-
ing and mice were monitored daily for survival. Animals 
were killed at the onset of neurologic signs or any type of 
distress.
Bioluminescent imaging (BLI)
Mice were imaged with the IVIS Imaging System 200 
Series (Caliper) to record bioluminescent signal emit-
ted from the engrafted tumors. Mice were anesthetized 
with isoflurane and received intraperitoneal injection of 
D-Luciferin (Caliper) at a dose of 270 µg/g body weight. 
Imaging acquisition was performed at 15 min after intra-
peritoneal injection of luciferin. For BLI analysis, regions 
of interest encompassing the intracranial area of signal 
were defined using Living Image software, and the total 
number of photons per second per steradian per square 
centimeter were recorded. To facilitate comparison of 
growth rates, each mouse’s luminescence readings were 
normalized against its own luminescence reading at 
day 12, thereby allowing each mouse to serve as its own 
control.
Statistical analysis
One-way analysis of variance with post hoc Scheffe 
analyses and Kaplan–Meier Survival Analysis with Tar-
one-Ware statistics were carried out using the SPSS 
package (version 18.0). The differences between control 
and experimental groups were determined by the two-
sided, unpaired Student t test. P  <  0.05 was considered 
significant.
Results
ROS is required for cycling hypoxia‑mediated HIF‑1α 
and NF‑κB activation
Our previous studies indicated that NADPH oxidase sub-
unit 4-mediated ROS contributes to the cycling hypoxia-
induced HIF-1α activation in glioblastoma cells [12–14]. 
However, the role of cycling hypoxia in NF-κB signal-
ing is still unclear. Therefore, we examined the effect 
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of experimentally imposed uninterrupted or cycling 
hypoxic stress on HIF-1α and NF-κB activation in glio-
blastoma cells. To assess HIF-1α and NF-κB activation 
under uninterrupted or cycling hypoxia in glioblastoma 
cells, the amount of HIF-1α and NF-κB protein in nuclear 
extracts was determined by western blot analysis after 
cells were exposed to hypoxic treatment in vitro. Under 
both uninterrupted and cycling hypoxic stress, HIF-1α 
and NF-κB protein levels increased in U87 or U251 glio-
blastoma cell nuclei (Fig. 1a). However, both HIF-1α and 
NF-κB protein levels in glioblastoma cells under cycling 
hypoxia stress were higher than those in cells under unin-
terrupted hypoxia stress. Moreover, reporter assays also 
showed that this effect further resulted in differences 
in HIF-1α and NF-κB signal transduction activities. As 
shown in Fig. 1b, c, both HIF-1α and NF-κB signal trans-
duction activities in the cycling hypoxia-treated cells 
were significantly increased after treatment in response 
to higher HIF-1α or NF-κB protein accumulation in cell 
nuclei. Next, we determined whether cycling hypoxia 
induced ROS contributes to HIF-1α and NF-κB activa-
tion. The glioblastoma cells were treated with Tempol 
during cycling hypoxia. When Tempol was administered 
following cycling hypoxia, the cycling hypoxia-induced 
H2DCF-DA response was completely suppressed 
(Fig. 1d). Furthermore, the increase in HIF-1α and NF-κB 
activation triggered by cycling hypoxia was abrogated 
(Fig.  1b, c). Taken together, these results indicate that 
cycling hypoxia promotes HIF-1α and NF-κB activation 
in glioblastoma cells via ROS.
Cycling hypoxia mediates Bcl‑xL expression via HIF‑1α or 
NF‑κB activation
It was previously reported that HIF-1α or NF-κB activa-
tion up-regulates the expression of Bcl-xL, thereby pre-
venting cell death at the mitochondrial level [20, 25]. 
Therefore, we next examined whether the regulation 
of Bcl-xL in glioblastoma cells was affected by cycling 
hypoxia-induced HIF-1α and NF-κB activation. We first 
evaluated the abundance of Bcl-xL at different times in 
the hypoxia-reoxygenation protocol in GBM8401 cells. 
Bcl-xL expression level was increased after each new 
cycle of hypoxia treatment (Fig. 2a, b). Bcl-xL mRNA and 
protein levels in GBM8401 cells under cycling hypoxia 
stress were significantly higher than those in GBM8401 
cells under uninterrupted hypoxia stress. In an attempt 
to gain insights into the role of HIF-1α or NF-κB on the 
regulation of Bcl-xL, we examined Bcl-xL expression in 
GMB8401cells lacking HIF-1α or NF-κB expression. 
Lentiviral transduction with shRNAs against HIF-1α or 
NF-κB resulted in the loss of HIF-1α or NF-κB expres-
sion in GBM8401 cells when compared with that in cells 
transduced with scrambled shRNA (Fig.  2c). HIF-1α 
or NF-κB knockdown in GBM8401 cells significantly 
Fig. 1 ROS is required for cycling hypoxia‑mediated HIF‑1α and NF‑κB activation. The levels of nuclear HIF‑1α and p65 (a), HIF‑1 dependent trans‑
activation of luciferase activity (b), NF‑κB‑dependent transactivation of luciferase activity (c), and intracellular ROS (d) in U251and U87 glioblastoma 
cells exposed to normoxia (Nor), uninterrupted hypoxia (NiH), or cycling hypoxia (CyH) (<1% O2) with or without Tempol. TATA‑binding protein 
(TBP) was used to normalize protein loading for nuclear extracts. Error bars denote the standard deviation within triplicate experiments. **P < 0.01, 
***P < 0.001 compared to normoxia. #P < 0.05, ###P < 0.001 compared to vehicle treatment
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Fig. 2 Cycling hypoxia mediates Bcl‑xL expression via HIF‑1α or NF‑κB activation. Bcl‑xL mRNA (a) and protein (b) levels in GBM8401 glioblastoma 
cells collected before and after 1 h of each of the 3 cycles of hypoxia (<1 % O2) during cycling hypoxia (CyH) and after 4 h of uninterrupted hypoxia 
(NiH). *P < 0.05, **P < 0.01, ***P < 0.001 compared to normoxia. c Western blot analysis of HIF‑1α or p65 knockdown in GBM8401 glioblastoma cells 
via the lentiviral‑based HIF‑1α or p65 shRNA. d, e Bcl‑xL mRNA and protein levels in GBM8401 glioblastoma cells transfected with or without scram‑
ble (Scr.), HIF‑1α, or p65 shRNA for 48 h followed by stimulation with cycling hypoxic stress for 4 h. ***P < 0.001 compared to normoxia (c). #P < 0.01, 
##P < 0.001 compared to Scr. shRNA treatment. f, g Bcl‑xL mRNA and protein levels in U251 and U87 cells treated with cycling hypoxic stress for 4 h 
in the absence or presence of HIF‑1α (YC‑1) and NF‑κB (Bay 11‑7082) inhibitors. Error bars denote the standard deviation within triplicate experi‑
ments. ***P < 0.001 compared to normoxia (Nor). ##P < 0.01, ###P < 0.001 compared to vehicle treatment
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inhibited cycling hypoxia-induced Bcl-xL expression 
(Fig. 2d, e). Moreover, glioblastoma cells, U87 and U251, 
were treated with specific HIF-1α (YC-1) and NF-κB (Bay 
11-7082) inhibitors during cycling hypoxic treatment. 
Bcl-xL mRNA and protein levels were upregulated after 
cycling hypoxia, but these effects were inhibited by YC-1 
and Bay 11-7082 treatment, suggesting that HIF-1α and 
NF-κB are critical signaling molecules involved in cycling 
hypoxia-induced Bcl-xL expression (Fig. 2f, g).
Cycling hypoxia‑mediated Bcl‑xL expression results 
in chemoresistance
Given the recognized role of Bcl-xL as an apoptosis 
suppressor, we determined whether cycling hypoxia-
mediated Bcl-xL up-regulation in glioblastoma cells was 
involved in the cell resistance to chemotherapy. Temo-
zolomide (TMZ) was chosen as the chemotherapy drug, 
because this drug has been widely used in the treatment 
of patients with glioblastoma [26]. The apoptotic changes 
were confirmed by detecting caspase activities and apop-
totic cells via the fluorogenic caspase-3 substrate and 
apoptosis assay, respectively. To investigate the role of 
Bcl-xL in hypoxia-mediated anti-apoptosis, Tet-regulata-
ble lentiviral vectors encoding shRNAs were used to sta-
bly and specifically knockdown Bcl-xL induction in U251 
and U87 cells under hypoxia. Q-PCR and western blot 
analysis showed that this shRNA successfully knocked 
down Bcl-xL expression in both cell lines after doxycy-
cline (Dox) treatment (Fig.  3a, b). We first used these 
cells to examine the effect of in vitro cycling hypoxic or 
uninterrupted hypoxic stress on TMZ-induced caspase 
activities and apoptosis in glioblastoma cells. Our results 
demonstrated that caspase activity and the number of 
apoptotic cells were significantly decreased by cycling 
hypoxia compared to those in normoxic cells or unin-
terrupted hypoxia-treated cells (Fig.  3c–f), suggesting 
that cycling hypoxic cells are resistant to TMZ-induced 
apoptosis. However, after Dox pretreatment, cycling 
hypoxia-induced chemoresistance was inhibited by Bcl-
XL knockdown. These results indicate that Bcl-XL plays 
an important role in cycling hypoxia-induced chemore-
sistance in glioblastoma cells.
Superoxide dismutase mimetic, Tempol, inhibits cycling 
hypoxia‑induced chemoresistance
The above findings suggest that cycling-induced Bcl-xL 
expression contributes the chemoresistance via ROS-
mediated HIF-1α and NF-κB activation. We next tested 
whether ROS blockage can improve cycling hypoxia-
induced chemoresistance. U251 and U87 cells were 
treated with Tempol under cycling hypoxia followed by 
TMZ treatment. MTT assays were used to determine 
TMZ cytotoxicity in glioblastoma cells. Cycling hypoxia 
significantly increased glioblastoma cell chemoresistance 
to TMZ compared to that of normoxic controls (Fig. 4a). 
When ROS was blocked by Tempol, the chemoresistance 
induced by cycling hypoxic stress decreased (Fig.  4b). 
To further determine the drug sensitivities of hypoxic 
cell subpopulations in glioblastoma xenografts, Hoechst 
33342 staining and HIF-1 activation labeling together 
with immunofluorescence imaging and fluorescence-
activated cell sorting were utilized to isolate hypoxic 
tumor subpopulations from human glioblastoma xeno-
grafts as described in our previous studies [6, 13, 14]. 
The chemoresistance increased significantly in cycling 
hypoxic cells (Hoechst 3342+ and GFP+) and chronic 
hypoxic cells (Hoechst 3342− and GFP+), compared 
with that in normoxic cells (Hoechst 3342+ and GFP−) 
(Fig. 4c). Moreover, treatment with Tempol significantly 
enhanced the TMZ-mediated cytotoxicity in cycling and 
chronic hypoxic cells, suggesting that the superoxide 
dismutase mimetic is able to improve tumor hypoxia-
induced chemoresistance.
Tempol inhibits cycling hypoxia‑induced Bcl‑xL induction 
and expression in vivo
We examined the role of ROS in cycling or uninter-
rupted hypoxia-mediated Bcl-xL induction. We first 
verified whether the transcriptional activation is 
involved in hypoxia-mediated Bcl-xL induction in glio-
blastoma cells. To achieve this, U87 and U251 glio-
blastoma cells were stably transfected with a lentiviral 
vector bearing the Bcl-xL promoter −1075 to +617 
region driven luciferase reporter gene that allowed for 
dynamic monitoring of the transcriptional activation of 
Bcl-xL. As shown in Fig. 5a, the transcriptional activa-
tion of Bcl-xL in the cycling hypoxia-treated cells was 
significantly increased after in  vitro cycling hypoxic 
treatment and this effect was inhibited by Tempol, 
YC-1, and Bay 11-7082. We next sought to investigate 
whether the effects observed in vitro were also detected 
in tumor-bearing mice. U87-Bcl-xL-P-Luc reporter cells 
were implanted subcutaneously into the flank of nude 
mice. The tumors developed 14 days later. In vivo opti-
cal imaging was used to record reporter activity in these 
tumors following in vivo cycling hypoxic treatment. The 
7  % O2 breathing conditions resulted in a tumor pO2 
of <2–3 mm Hg. In vivo optical imaging demonstrated 
that significantly enhanced levels of luciferase activ-
ity were detectable in the animals subjected to cycling 
hypoxic stress (Fig.  5b, c). However, cycling hypoxia-
induced transcriptional activation of Bcl-xL was 
inhibited in mice treated with Tempol, YC-1, and Bay 
11-7082 followed by in  vivo cycling hypoxic treatment 
(Fig. 5b, c). Western blotting of homogenized tumor tis-
sues confirmed the effect on Bcl-xL protein expression 
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levels (Fig.  5d). Besides, the total RNA of the hypoxic 
cell subpopulations derived from disaggregated ortho-
topic GBM8401/hif-1-r and U87/hif-1-r xenografts [6] 
were further analyzed for Bcl-xL expression by Q-PCR. 
Bcl-xL expression significantly increased in cycling and 
chronic hypoxic cells compared with that in normoxic 
cells (Fig. 5e). These data indicated that cycling hypoxic 
stress resulted in significantly elevated levels of Bcl-xL 
induction in glioblastoma cells and xenografts. ROS 
and their downstream transcription factors, HIF-1α 
and NF-κB, are critical mediators involved in cycling 
hypoxia-mediated Bcl-xL induction.
Fig. 3 Cycling hypoxia‑mediated Bcl‑xL expression results in chemoresistance. a Verification of Bcl‑xL knockdown by Tet‑regulatable lentiviral 
knockdown system at the mRNA (a) and protein (b) levels. The lentiviral infected cells were treated for 48 h with Dox (0.04 μg/mL) to induce Bcl‑xL 
knockdown. Error bars denote the standard deviation among triplicate experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared to no Dox treat‑
ment. Caspase‑3 activity (c, d) and percentage of apoptotic cells (e, f) in U251 and U87 cells cultured in normoxia, uninterrupted (NiH) hypoxia 
(<1 % O2), and cycling (CyH) hypoxia (<1 % O2) with or without Bcl‑xL knockdown in response to temozolomide (TMZ) treatment. Cells were 
pretreated for 48 h with Dox (0.04 μg/mL) to induce Bcl‑xL knockdown and exposed to hypoxic stresses before TMZ treatment. Error bars denote 
the standard deviation among triplicate experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared to control without any treatment. #P < 0.05, 
##P < 0.01 compared to normoxia with TMZ treatment
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Tempol enhances the efficiency of TMZ chemotherapy 
in mice bearing intracranial glioblastoma xenografts
Finally, we investigated whether ROS scavenger repre-
sents a viable approach to inhibit tumor microenviron-
ment-mediated therapy resistance in GBM. We sought 
to test the efficacy of Tempol in combination with TMZ 
treatment. BLI was utilized to assess intracranial tumor 
growth in the orthotopic GBM8401/SFFV-LucGFP xen-
ograft model. Consistent with the in  vitro studies, mice 
treated with Tempol prior to initiation of the TMZ treat-
ment presented with a significantly increased tumor 
growth delay and survival rate than those pretreated 
with vehicle (Fig. 6a–c). The Tempol and TMZ combina-
tion treatment yielded synergistic effects. These results 
suggest that ROS scavenger enhances the efficiency of 
TMZ chemotherapy in  vivo in orthotopic glioblastoma 
xenografts.
Discussion
There is abundant evidence to suggest that cycling 
hypoxia as well as uninterrupted hypoxia play roles in 
many aspects of tumor growth and development [27, 28]. 
However, some results demonstrated that cycling hypoxia 
would utilize different intracellular signaling path-
ways than those utilized by uninterrupted hypoxia. For 
instance, ROS might play a vital role in cycling hypoxia-
induced alterations in the carotid body function [29]. 
In addition, the expression of immediate early response 
genes and transcription factors, AP-1 and HIF-1, were 
activated by cycling hypoxia [29]. These results suggest 
that signaling pathways associated with transcriptional 
regulation by cycling hypoxia are distinct from those uti-
lized by uninterrupted hypoxia. Consistent with these 
findings, our data showed that ROS production is only 
significantly triggered by cycling hypoxia in glioblastoma 
Fig. 4 Superoxide dismutase mimetic, Tempol, inhibits cycling hypoxia‑induced chemoresistance. a Cytotoxicity assay of normoxia (Nor), uninter‑
rupted hypoxia (NiH), and cycling hypoxia (CyH)‑mediated temozolomide (TMZ) sensitivity in U251 and U87 glioblastoma cells. *P < 0.05 compared 
to Nor with TMZ treatment. b Cytotoxicity assay after Tempol treatment revealed increased TMZ cytotoxicity and suppression of cycling hypoxia 
(CyH)‑mediated TMZ resistance in U251 and U87 glioblastoma cells. *P < 0.05, **P < 0.01, ***P < 0.001 compared to CyH without any treatment, 
###P < 0.001 compared to CyH with TMZ treatment. c Cytotoxicity assay of TMZ in normoxic tumor cells (Hoechst 3342+ and GFP−), chronic hypoxic 
tumor cells (Hoechst 3342− and GFP+), and cycling hypoxic tumor cells (Hoechst 3342+ and GFP+) isolated from disaggregated U87/hif‑1‑r xeno‑
grafts. *P < 0.05, **P < 0.01 compared to normoxic tumor cells (Hoechst 3342+ and GFP−). Error bars denote the standard deviation among triplicate 
experiments
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Fig. 5 Tempol inhibits cycling hypoxia‑induced Bcl‑xL induction and expression in vivo. a Bcl‑xL promoter‑dependent transactivation of luciferase 
activity in U251 and U87 cells cultured in normoxia (Nor) and cycling (CyH) hypoxia (<1 % O2) with or without pretreatment with Tempol, YC‑1, or 
Bay 11‑7082. ***P < 0.001 compared to Nor. #P < 0.05, ##P < 0.01, ###P < 0.001 compared to CyH with vehicle treatment. b In vivo bioluminescence 
(BLI) images of the transcriptional activation of Bcl‑xL in U87 glioblastoma xenografts before and after Tempol, YC‑1, or Bay 11‑7082 treatment. c 
Quantitative data obtained from the BLI imaging of the transcriptional activation of Bcl‑xL in U87 xenografts. Data represent the mean ± standard 
deviation of average counts within the tumor region of interest in BLI from 6 mice. ***P < 0.001 compared to Nor. #P < 0.05, ##P < 0.01, ###P < 0.001 
compared to CyH with vehicle treatment. d Bcl‑xL protein levels in homogenized tumor tissues derived from the above groups. e Bcl‑xL mRNA 
levels in normoxic cells (Hoechst 3342+ and GFP−), chronic hypoxic cells (Hoechst 3342− and GFP+), and cycling hypoxic cells (Hoechst 3342+ and 
GFP+) isolated from disaggregated GBM8401/hif‑1‑r and U87/hif‑1‑r xenografts. ***P < 0.001 compared to normoxic tumor cells (Hoechst 3342+ 
and GFP−). Error bars denote the standard deviation within triplicate experiments
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cells. Therefore, the ROS-mediated HIF-1/NF-κB/Bcl-
xL pathway is activated only in cycling hypoxia-treated 
glioblastoma cells. Furthermore, cycling hypoxia induced 
more chemoresistance than uninterrupted hypoxia in 
U87 or U251 glioblastoma cells.
Highly aggressive tumors are known to be exposed to 
hypoxia, which occurs as a result of inadequate blood 
supply [30]. Since hypoxia can affect certain gene regu-
latory mechanisms and signal transduction pathways, 
including tumor cell apoptosis, metastasis, and tumor 
angiogenesis, deciphering the hypoxic tumor cell 
response is essential to understand tumor progression. 
HIF-1α is a master transcription factor that regulates 
both physiological and pathophysiological responses 
of mammalian cells to hypoxia [31]. In addition, it is 
also regulated by other factors, including oncogenes, 
growth factors, and free radicals [32]. It is well known 
that HIF-1α overexpression driven by hypoxia and free 
radical species contributes to therapy resistance [2, 10]. 
Several signaling pathways have been proposed to be 
regulated by hypoxia. For example, hypoxia could acti-
vate the JNK and p38 stress kinases in human squamous 
carcinoma cells and further leads to phosphorylation of 
transcription factor ATF-2 [33]. Moreover, HIF-1α sign-
aling associated with p38 involves mitochondrial-derived 
ROS [34]. Furthermore, we previously demonstrated that 
cycling hypoxia induces HIF-1 activity via ROS-mediated 
HIF-1α synthesis and stabilization in U87 glioblastoma 
cells [10].
Constitutive activation of NF-κB frequently occurs in 
various cancer types and is important for cancer cells to 
escape apoptosis and survive in the presence of apoptotic 
stimuli [35]. Therefore, cancer cell resistance to chemo-
therapeutic agents can be partly explained by NF-κB 
deregulation. Inhibition of NF-κB activity could sensitize 
hepatocellular carcinoma cells to doxorubicin-induced 
apoptosis [36]. In addition, NF-κB is activated by hypoxia 
and plays a central role in gene regulation under hypoxia/
reoxygenation [37, 38]. However, to date, the involvement 
of ROS in NF-κB signaling is controversial. For example, 
Fig. 6 Tempol enhances the efficiency of TMZ chemotherapy in mice bearing intracranial glioblastoma xenografts. a Bioluminescent images from 
control (vehicle) and animals treated with Tempol, TMZ, and Tempol plus TMZ on day 20 after tumor implantation. b The mean normalized BLI val‑
ues associated with longitudinal monitoring of intracranial tumor growth for each treatment group. Error bars denote the standard deviation among 
9 mice per group. c The corresponding survival curves of GBM8401 xenograft‑bearing mice for each treatment group
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some reports suggested that NF-κB is not a sensor of oxi-
dative stress and ROS does not influence NF-κB activa-
tion during intermittent hypoxia/reoxygenation [39, 40]. 
In contrast, our results show that cycling hypoxia induces 
HIF-1α and NF-κB activation through ROS generation 
and this activation dramatically decreases after Tempol 
treatment in both U87 and U251 glioblastoma cells. A 
recent review article also highlights that ROS have vari-
ous inhibitory or stimulatory roles in NF-κB signaling, 
suggesting the complexity of ROS-mediated NF-κB sign-
aling [41].
GBM is the most malignant form of brain cancer with 
a high mortality rate and this aggressive capability may 
be partly due to tumor hypoxia [42, 43]. It contains mul-
tiple hypoxic areas that exhibit elevated HIF-1 signal 
transduction activity, resulting in the deregulated expres-
sion of downstream target genes that contribute to GBM 
malignancy [44]. The expression of BNIP3, a Bcl-2 fam-
ily member, correlates with HIF-1α expression levels in 
various types of tumor cells. Its expression was predomi-
nantly detected in the nucleus under hypoxic stress and 
contributes to cell survival in GBM [45]. The Bcl-xL and 
Bcl-2 proteins are dominant inhibitors of apoptotic cell 
death. Recent studies demonstrated that Bcl-xL is one 
of the downstream target genes of HIF-1α and NF-κB 
through transcriptional regulation [19, 20, 25]. Therefore, 
we proposed that the activation of HIF-1α and NF-κB 
induced by ROS under cycling hypoxia could result in 
Bcl-xL induction and allow the survival of glioblastoma 
cells. Our results clearly indicate that cycling hypoxia 
induces Bcl-xL expression in vivo and in vitro via HIF-1α 
or NF-κB activation and these effects can be inhibited 
by Tempol, HIF-1α inhibitor, or NF-κB inhibitor treat-
ment. ROS and their downstream transcription factors, 
HIF-1α and NF-κB, are critical mediators involved in 
cycling hypoxia-mediated Bcl-xL induction. In addi-
tion, unlike uninterrupted hypoxia treatment, cycling 
hypoxia induces prosurvival effects in glioblastoma cells 
in response to Bcl-xL induction and caspase-3 inhibition. 
Moreover, cycling hypoxia significantly increases chem-
oresistance to TMZ compared with normoxic conditions 
in U87 or U251 glioblastoma cells. This chemoresist-
ance induced by cycling hypoxic stress was suppressed 
by a ROS scavenger as well as by HIF-1α and NF-κB 
inhibitors. Therefore, ROS mediated HIF-1α and NF-κB 
activation is a crucial mechanism involved in cycling 
hypoxia-induced anti-apoptosis and chemoresistance in 
glioblastoma cells. These findings are important in the 
selection of optimal strategies for anticancer therapy in 
GBM.
In conclusion, the present study provides insightful 
information regarding the differential regulatory mecha-
nisms involved in cycling hypoxia and uninterrupted 
hypoxia in tumor chemosensitivity. In addition, our 
data also highlight the putative mechanisms of cycling 
hypoxia in tumor cell chemoresistance in glioblastoma 
and suggest that ROS are attractive therapeutic targets 
to counteract cycling hypoxia-induced chemoresistance. 
Our previous studies also suggests that ROS within GBM 
cells act as second messengers in intracellular signaling 
cascades, which contribute to cycling hypoxia-mediated 
tumor progression [12, 14]. Since cycling hypoxia is now 
a well-recognized phenomenon in the tumor microen-
vironment [2], ROS blockade should be used before and 
with chemotherapy to suppress cycling hypoxia-induced 
chemoresistance and tumor progression and to further 
enhance the therapeutic efficiency of cytotoxic therapies 
in GBM.
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